A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Anti-angiogenesis therapy, a promising strategy against cancer progression, is limited by
drug-resistance, which could be attributed to changes within the tumor microenvironment …

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell
lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular …

Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Background and Aims Activation of the antitumor immune response using programmed
death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients with …

Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not
the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests …

As one of the most common forms of solid tumours, gastric carcinoma has been revealed as
the third leading cause of death worldwide. The symptom of gastric cancer is usually not …

Gastric cancer is the fifth most common cancer and the third most common cause of cancer
death globally. Risk factors for the condition include Helicobacter pylori infection, age, high …

Metastasis remains a pivotal characteristic of cancer and is the primary contributor to cancer-
associated mortality. Despite its significance, the mechanisms governing metastasis are not …

Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could
potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T …